Differentially expressed epigenome modifiers, including aurora kinases A and b, in immune cells in rheumatoid arthritis in humans and mouse models

Arthritis and Rheumatism

Volumn 65, Issue 7, 2013, Pages 1725-1735

  Glant, Tibor T ^a   Besenyei, Timea ^a   Kádár, András ^a   Kurkó, Júlia ^a   Tryniszewska, Beata ^a   Gál, János ^b   Soós, Györgyi ^b   Szekanecz, Zoltán ^c   Hoffmann, Gyula ^d   Block, Joel A ^a   Katz, Robert S ^a   Mikecz, Katalin ^a   Rauch, Tibor A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b 1st Department of Internal Medicine   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; HISTONE H3; TOZASERTIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTONES; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; UP-REGULATION;

EID: 84879865537     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37986     Document Type: Article

References (45)

1. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL,. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62: 722-7.
2. Ballestar E,. Epigenetic alterations in autoimmune rheumatic diseases. Nat Rev Rheumatol 2011; 7: 263-71.
3. Jacobi AM, Dorner T,. Current aspects of anti-CD20 therapy in rheumatoid arthritis. Curr Opin Pharmacol 2010; 10: 316-21.
4. Chi P, Allis CD, Wang GG,. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010; 10: 457-69.
5. Carmena M, Ruchaud S, Earnshaw WC,. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins. Curr Opin Cell Biol 2009; 21: 796-805.
6. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W,. Aurora kinase inhibitors-rising stars in cancer therapeutics? Mol Cancer Ther 2010; 9: 268-78.
7. Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H, et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 2002; 22: 874-85.
8. Mikecz K, Glant TT, Poole AR,. Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan. Arthritis Rheum 1987; 30: 306-18.
9. Glant TT, Mikecz K,. Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis. Methods Mol Med 2004; 102: 313-38.
10. Glant TT, Radacs M, Nagyeri G, Olasz K, Laszlo A, Boldizsar F, et al. Proteoglycan-induced arthritis and recombinant human proteoglycan aggrecan G1 domain-induced arthritis in BALB/c mice resembling two subtypes of rheumatoid arthritis. Arthritis Rheum 2011; 63: 1312-21.
11. Mikecz K, Brennan FR, Kim JH, Glant TT,. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat Med 1995; 1: 558-63.
12. Adarichev VA, Valdez JC, Bardos T, Finnegan A, Mikecz K, Glant TT,. Combined autoimmune models of arthritis reveal shared and independent qualitative (binary) and quantitative trait loci. J Immunol 2003; 170: 2283-92.
13. Myers LK, Seyer JM, Stuart JM, Kang AH,. Suppression of murine collagen-induced arthritis by nasal administration of collagen. Immunology 1997; 90: 161-4.
14. Glant TT, Adarichev VA, Nesterovitch AB, Szanto S, Oswald JP, Jacobs JJ, et al. Disease-associated qualitative and quantitative trait loci in proteoglycan-induced arthritis and collagen-induced arthritis. Am J Med Sci 2004; 327: 188-95.
15. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM,. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A 2010; 107: 13836-41.
16. Taylor S, Wakem M, Dijkman G, Alsarraj M, Nguyen M,. A practical approach to RT-qPCR-publishing data that conform to the MIQE guidelines. Methods 2010; 50: S1-5.
17. Tate CM, Lee JH, Skalnik DG,. CXXC finger protein 1 contains redundant functional domains that support embryonic stem cell cytosine methylation, histone methylation, and differentiation. Mol Cell Biol 2009; 29: 3817-31.
18. Boldizsar F, Kis-Toth K, Tarjanyi O, Olasz K, Hegyi A, Mikecz K, et al. Impaired activation-induced cell death promotes spontaneous arthritis in antigen (cartilage proteoglycan)-specific T cell receptor-transgenic mice. Arthritis Rheum 2010; 62: 2984-94.
19. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
20. Beck IM, Vanden Berghe W, Vermeulen L, Bougarne N, Vander CB, Haegeman G, et al. Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-κB inhibition. EMBO J 2008; 27: 1682-93.
21. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 1997; 278: 860-6.
22. Angyal A, Egelston C, Kobezda T, Olasz K, Laszlo A, Glant TT, et al. Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints. Arthritis Res Ther 2010; 12: R44.
23. Cantaert T, Kolln J, Timmer T, van der Pouw Kraan TC, Vandooren B, Thurlings RM, et al. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol 2008; 181: 785-94.
24. Dorner T, Radbruch A, Burmester GR,. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009; 5: 433-41.
25. Kotzin BL,. The role of B cells in the pathogenesis of rheumatoid arthritis. J Rheumatol Suppl 2005; 73: 14-8.
26. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-7.
27. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI,. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006; 66: 7668-77.
28. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L,. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A 2003; 100: 1931-6.
29. Karouzakis E, Gay RE, Gay S, Neidhart M,. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol 2009; 5: 266-72.
30. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M,. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60: 3613-22.
31. Huber LC, Brock M, Hemmatazad H, Giger OT, Moritz F, Trenkmann M, et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007; 56: 1087-93.
32. Meinecke I, Cinski A, Baier A, Peters MA, Dankbar B, Wille A, et al. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc Natl Acad Sci U S A 2007; 104: 5073-8.
33. Ospelt C, Gay S,. The role of resident synovial cells in destructive arthritis. Best Pract Res Clin Rheumatol 2008; 22: 239-52.
34. Wolter S, Doerrie A, Weber A, Schneider H, Hoffmann E, von der Ohe J, et al. c-Jun controls histone modifications, NF-κB recruitment, and RNA polymerase II function to activate the ccl2 gene. Mol Cell Biol 2008; 28: 4407-23.
35. Levy D, Kuo AJ, Chang Y, Schaefer U, Kitson C, Cheung P, et al. Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling. Nat Immunol 2011; 12: 29-36.
36. Levy D, Liu CL, Yang Z, Newman AM, Alizadeh AA, Utz PJ, et al. A proteomic approach for the identification of novel lysine methyltransferase substrates. Epigenetics Chromatin 2011; 4: 19.
37. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009; 10: 92-100.
38. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 2010; 11: 936-44.
39. Jeon YJ, Lee KY, Cho YY, Pugliese A, Kim HG, Jeong CH, et al. Role of NEK6 in tumor promoter-induced transformation in JB6 C141 mouse skin epidermal cells. J Biol Chem 2010; 285: 28126-33.
40. Kishimoto T,. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-52.
41. Mori T, Miyamoto T, Yoshida H, Asakawa M, Kawasumi M, Kobayashi T, et al. IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 2011; 23: 701-12.
42. Leandro MJ, Becerra-Fernandez E,. B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011; 25: 535-48.
43. Nakken B, Munthe LA, Konttinen YT, Sandberg AK, Szekanecz Z, Alex P, et al. B-cells and their targeting in rheumatoid arthritis-current concepts and future perspectives. Autoimmun Rev 2011; 11: 28-34.
44. Yazici Y,. Long-term safety of methotrexate in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: S65-7.
45. Albrecht K, Muller-Ladner U,. Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: S95-101.